Zymergen Inc.: insider trades · United States · SEC (Form 4)

About Zymergen Inc.

Zymergen Inc. was a U.S.-based industrial biotechnology company founded in 2013 by Joshua Hoffman, Zach Serber, and Jed Dean. Its headquarters were in Emeryville, California, United States, and it was listed on the U.S. NASDAQ market. For European investors, Zymergen sat at the intersection of synthetic biology, advanced materials, and specialty chemicals, with a business model focused on engineering microorganisms to produce molecules and materials traditionally derived from petrochemicals. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Zymergen?utm_source=openai)) From a historical perspective, Zymergen raised substantial capital to build a platform combining genomics, automation, and machine learning. The company’s long-term thesis was to create industrial inputs that could be safer, more sustainable, and potentially cheaper than conventional manufacturing routes. In market terms, Zymergen became known as an ambitious “deep tech” industrial biotech story, attracting attention for its attempt to replace petroleum-based materials with biologically produced alternatives. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Zymergen?utm_source=openai)) Operationally, the company’s core activity centered on R&D for engineered microbes and bio-manufacturing processes. Its product and technology offering was geared toward materials and chemical intermediates for consumer electronics and other industrial applications. The best-known commercial product was Hyaline, a bio-manufactured polyimide film described as transparent and flexible, designed for certain electronic-use cases. Zymergen also communicated about broader potential applications across consumer goods and pharmaceuticals, reflecting the platform nature of its technology stack. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Zymergen?utm_source=openai)) In competitive terms, Zymergen tried to differentiate itself through a technology-intensive, data-driven approach to industrial biology. However, execution proved difficult. SEC-related materials and restructuring disclosures indicate that the company faced major scale-up, commercialization, and industrial validation challenges, which undermined its revenue generation and ultimately its public-market narrative. That combination of high R&D intensity and weak near-term monetization made the equity story highly speculative. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Zymergen?utm_source=openai)) Recent developments are decisive. In 2022, Ginkgo Bioworks announced an acquisition involving Zymergen, and SEC filings show that Ginkgo completed the acquisition of substantially all of Zymergen’s assets on January 18, 2024. Zymergen’s plan of liquidation was then confirmed by the bankruptcy court on February 5, 2024. As a result, Zymergen no longer functions as an independent public company. For investors, that means the name is now primarily relevant as a completed restructuring/bankruptcy case rather than an ongoing listed equity story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1830214/000162828024022229/dna-20240331.htm?utm_source=openai))